Related Experiment Video

Updated: Aug 14, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Cardiovascular issues of COX-2 inhibitors and NSAIDs

Melinda Wong1, Phil Chowienczyk, Bruce Kirkham

  • 1Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria. melinda.wong@svhm.org.au

Australian Family Physician
|November 22, 2005
PubMed
Abstract

Insights

Selective COX-2 inhibitors like rofecoxib and celecoxib increase cardiovascular risk. Non-steroidal anti-inflammatory drugs (NSAIDs) may also pose risks, necessitating cautious use and lowest effective doses.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Safety

Background:

  • Rofecoxib (Vioxx) withdrawal due to increased cardiovascular (CV) death.
  • Potential shared CV risk among other selective cyclooxygenase-2 (COX-2) inhibitors and traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

Purpose of the Study:

  • Review evidence on CV risk associated with COX-2 inhibitors and NSAIDs.
  • Explore potential mechanisms underlying this risk.
  • Provide recommendations for clinical use.

Main Methods:

  • Systematic literature review of PubMed for studies on COX-2 inhibitors, NSAIDs, and CV risk.
  • Analysis of prospective trials and observational studies.
  • Synthesis of evidence to inform clinical practice guidelines.

Main Results:

  • Prospective trials confirm increased CV risk with rofecoxib, celecoxib, and valdecoxib/parecoxib combinations.
  • Observational studies suggest NSAIDs are associated with increased CV risk, requiring further large-scale randomized trials.
  • Evidence points to a dose- and duration-dependent risk.

Conclusions:

  • COX-2 inhibitors are contraindicated in patients with or at high risk for CV disease.
  • Lowest effective doses and shortest possible durations are recommended for all NSAIDs and COX-2 inhibitors.
  • Consider traditional NSAIDs with proton pump inhibitors cautiously in high-risk patients, balancing risks and benefits.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...